CKD-MBD Insights and Innovations for 2025 and Beyond: No Bone Left Uncovered

7 Feb 2025 9:45 a.m. 11:15 a.m.

Gulmohar Hall 302

ArvindBagga Chair India

UttaraDas Chair IndiaAll IndiaInstitute of Medical Science Mangalagiri

Session Description:
Hear from the experts about the pathophysiology of CKD-MBD from childhood to the elderly and applying this knowledge in everyday clinical practice. Gain a balanced view of mineral bone disease in CKD, by reviewing a European consensus report and the recent KDIGO controversies conference. Get an update on the challenges and opportunities of existing and emerging bone biomarkers for the evaluation of bone disease in CKD.
Learning Objectives:
Understanding CKD-MBD management to optimise treatment. Interpreting bone biomarkers

Time	Session

9:45 a.m. 10:03 a.m.	What Should a Clinician Know About CKD-MBD in 2025? LF01-01 HanneJoergensen Speaker hsjorgensen@clin.au.dkDenmarkAarhus University
10:03 a.m. 10:21 a.m.	CKD-MBD in Children and Young Adults: What's the Difference? LF01-02 SukanyaGovindan Speaker sukanyagovindan@gmail.comIndiaMehta Children's Hospitals and MGM healthcare, Chennai, India
10:21 a.m. 10:39 a.m.	Progress in CKD-driven Vascular Calcification: From Bench to Bedside LF01-03 MarcVervloet Speaker Marc.Vervloet@radboudumc.nlNetherlandsRadboud University Medical center, The Netherlands
10:39 a.m. 10:57 a.m.	How to Use Serum Biomarkers for Optimal Management of CKD-MBD LF01-04 SandroMazzaferro Speaker sandro.mazzaferro@uniroma1.itItalySapienza University of Rome, Italy
10:57 a.m. 11:15 a.m.	Q&A LF01-05